Synergistic disruption of ERα/HER2 crosstalk by endoxifen and lapatinib in breast cancer cells

Chan, James Chun Yip; Ong, Pei Shi; Lim, Peirong; Teng, Preben Xiang Long; Chan, Eric Chun Yong

doi:10.1007/s00280-016-3211-7

Cited by 2 publications

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Accordingly, further investigation and research have been conducted to evaluate the benefit of extended dual ER/HER2 blockade and HER2 receptor inhibition. To date, dual blockade of ER/HER2 signaling using combinations of agents that directly target ER (e.g., selective estrogen receptor degraders [SERDs], selective estrogen receptor modulators [SERMs], AIs) and HER2 (e.g., monoclonal antibodies [mAbs] or small-molecule TKIs) have proven to be highly effective in preclinical models (cataloged in Table 1) 23,41,42,[46][47][48][49][50][51][52][53][54][55] .…”

Section: Dual Er and Her2 Signaling: Preclinical Evidencementioning

confidence: 99%

Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer

Pegram¹,

Jackisch

Johnston

2023

npj Breast Cancer

View full text Add to dashboard Cite

The human epidermal growth factor receptor 2 (HER2) is overexpressed in 13–22% of breast cancers (BC). Approximately 60–70% of HER2+ BC co-express hormone receptors (HRs). HR/HER2 co-expression modulates response to both anti-HER2–directed and endocrine therapy due to “crosstalk” between the estrogen receptor (ER) and HER2 pathways. Combined HER2/ER blockade may be an effective treatment strategy for patients with HR+/HER2+ BC in the appropriate clinical setting(s). In this review, we provide an overview of crosstalk between the ER and HER2 pathways, summarize data from recently published and ongoing clinical trials, and discuss clinical implications for targeted treatment of HR+/HER2+ BC.

show abstract

Section: Dual Er and Her2 Signaling: Preclinical Evidencementioning

confidence: 99%

Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer

Pegram¹,

Jackisch

Johnston

2023

npj Breast Cancer

View full text Add to dashboard Cite

show abstract

“…Berberine at certain concentrations was reported to inhibit the growth of TAM-sensitive MCF7 and MCF7-TAM R cells (16). BT-474, a breast cancer cell line overexpressing HER2, also exhibits resistance to TAM treatment (20). This study first examined the inhibitory effect of berberine on MCF7-TAM R and BT-474 cells using MTT assays.…”

Section: Sensitization Of Breast Cancer Cells To Tam By Berberinementioning

confidence: 99%

Enhancement of Sensitivity to Tamoxifen by Berberine in Breast Cancer Cells by Inhibiting ER-α36 Expression

et al. 2022

View full text Add to dashboard Cite

: Berberine, an isoquinoline alkaloid purified from Chinese herbs, was verified to have antitumor effects. It has also been reported that berberine can enhance the anticancer effect of tamoxifen (TAM) in estrogen receptor (ER)-positive breast cancer cells; however, the involved underlying mechanism is still unclear. In the present study, the role of one variant of ER-α, ER-α36, in the TAM sensitizing effect of berberine was explored in TAM-resistant breast cancer cells. This study demonstrated that berberine potently sensitized TAM-resistant breast cancer cells, including TAM-resistant MCF7 and BT-474 cells, to TAM treatment. Additionally, this study showed that berberine could simultaneously suppress ER-α36 expression in TAM-resistant cells. However, when ER-α36 was knocked down in TAM-resistant cells, there was no significant TAM-sensitizing effect by berberine. Therefore, this study indicated that ER-α36 is involved in berberine’s TAM-sensitizing effect on ER-positive breast cancer cells, which provided supporting data for the application of berberine in cancer therapy as an adjuvant agent for TAM treatment.

show abstract

Synergistic disruption of ERα/HER2 crosstalk by endoxifen and lapatinib in breast cancer cells

Cited by 2 publications

References 39 publications

Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer

Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer

Enhancement of Sensitivity to Tamoxifen by Berberine in Breast Cancer Cells by Inhibiting ER-α36 Expression

Contact Info

Product

Resources

About